Lucid Diagnostics is a highly differentiated, multi-product medical device innovator founded and managed by entrepreneurs with a successful track record of developing and commercializing novel medical technologies.
Lucid’s core mission is to save lives by detecting BE in a highly accurate and cost-efficient manner while it can be effectively managed or treated to prevent progression to deadly esophageal cancer.
Lucid Diagnostics is developing a revolutionary technology as a non-invasive, office-based targeted cell collection device (EsoCheck) and a lab-based, DNA biomarker test (EsoGuard) to detect the precursor condition (Barrett’s Esophagus or BE) to highly lethal esophageal cancer.
Lucid’s technology was highlighted in the National Cancer Institute’s 2020 Annual Plan and Budget Proposal to Congress as one of the year’s significant advances in cancer prevention and has been shown to be highly accurate at detecting BE in a published study.
Lucid is pursuing a two-phase strategy seeking to maximize the EsoGuard technology’s long-term commercial opportunity while providing near-term value-inflection milestones.
The first phase seeks to launch EsoGuard as a lab-developed test (LDT) while separately commercializing EsoCheck as an FDA 510(k)-cleared cell collection device. The second phase seeks an indication for widespread screening using EsoGuard on samples collected by EsoCheck through the FDA de novo or PMA regulatory pathway.
Lucid Diagnostics is a subsidiary of PAVmed Inc.